FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
FTC releases second report slamming pharmacy benefit managers
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer — but relies on more data.
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
FTC says pharmacy benefits managers marked-up generic drug prices for $7.3bn gain
Regulator’s report finds companies ‘hiked costs’ for a range of medicines, including cancer and HIV treatments
FTC finds top 3 PBMs inflated drug prices by $7.3B
The three PBMs inflated the drug prices dispensed at their affiliated pharmacies by hundreds and thousands of percent passing costs onto patients, employers and healthcare plans, according to a Jan. 14 news release from the agency.
FTC finds PBMs excessively marked up prices on specialty drugs
A new report issued by the Federal Trade Commission has found that prescription benefit manager units owned by CVS Health (NYSE:CVS), Cigna (CI) and UnitedHealth Group (UNH) significantly marked up prices for many specialty generic drugs over a six-year period.
CVS Health: Current Price Offers Favorable Risk-Reward Profile
The Health Care Benefits segment includes Aetna and other health insurance businesses. CVS acquired Aetna in 2017. In 2023, ...
Hosted on MSN1d
What You Need To Know Ahead of CVS Health's Earnings Release
With a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide ...
After Falling More Than 40% in 2024, Can CVS Health Stock Turn Things Around This Year?
CVS Health ( CVS 4.35%) is a stock that's been struggling badly for multiple years and is coming off a brutal performance in ...
Wedmont Private Capital Reduces Position in CVS Health Co. (NYSE:CVS)
Wedmont Private Capital lessened its holdings in shares of CVS Health Co. (NYSE:CVS – Free Report) by 21.5% in the fourth ...
Crain's New York3d
Aetna offers NY employers new strategies to control health care and pharmacy costs
In this Q&A, Joe Dorazio, Small Group Head of Sales – at Aetna ®, a CVS Health ® Company, addresses common questions about ...
CVS Health Corp. (NYSE:CVS): Is there more Downside to the Stock?
An analysis by natey1015 on ValueInvestorsClub offers a bearish perspective for CVS Health, a stock that has fallen by almost ...
Claro Advisors LLC Decreases Stake in CVS Health Co. (NYSE:CVS)
Claro Advisors LLC trimmed its position in shares of CVS Health Co. (NYSE:CVS – Free Report) by 59.7% during the fourth ...
Wells Fargo Reaffirms Their Buy Rating on CVS Health (CVS)
Wells Fargo analyst Stephen Baxter maintained a Buy rating on CVS Health (CVS – Research Report) on January 10 and set a price target of ...